BioCorRx Inc. (OTC: BICX), a developer and provider of innovative treatment support programs for substance use disorders, announced on September 10, 2026, the appointment of Richard J. Baum to its Strategic Advisory Board. Baum, a former Acting Director of the White House Office of National Drug Control Policy (ONDCP) and former Executive Director of the President's Commission on Combating Drug Addiction and the Opioid Crisis, brings nearly three decades of federal drug policy and addiction expertise to the role. His addition signals BioCorRx's intent to strengthen its strategic positioning amid a persistent national overdose crisis.
Baum's career at ONDCP spanned 28 years and six presidential administrations, where he helped shape federal responses to evolving drug threats, including the opioid crisis. His experience covers treatment and recovery policy, prevention, public safety, interagency coordination, and collaboration with state and local partners. As an Adjunct Professor at Georgetown University's McCourt School of Public Policy and author of Inside America's Opioid Crisis: 12 Hard Lessons for Today's Drug War, Baum also serves on the United Against Fentanyl Board of Directors. His recent writing on the opioid crisis has appeared in The Lancet.
BioCorRx expects to draw on Baum's policy and systems-level expertise as it advances its treatment and pharmaceutical strategies. The company's offerings include LUCEMYRA® (lofexidine), an FDA-approved non-opioid medication indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults, and BICX104, its investigational biodegradable naltrexone implant technology. Baum's perspective will also support the company's engagement with treatment and recovery organizations, public health agencies, healthcare systems, justice-system partners, policymakers, and other stakeholders.
Lourdes Felix, Chief Executive Officer of BioCorRx Inc., said, "Rich has spent his career at the intersection of drug policy, public health, treatment, and public safety, and we are honored to welcome him to BioCorRx. His deep understanding of how policy translates into real-world treatment access will be invaluable as we work to expand awareness of evidence-based approaches to addiction treatment and thoughtfully position our programs within the broader continuum of care."
Baum commented, "I am pleased to join BioCorRx as a strategic advisor at a time when the country continues to face significant challenges related to opioid use, addiction treatment, and recovery. BioCorRx is working across several important points in the treatment continuum, including managing opioid withdrawal symptoms with LUCEMYRA. In an era of increasingly dangerous polysubstance use, particularly involving illicit fentanyl and methamphetamine, I am also encouraged by the Company's research evaluating BICX104, an investigational long-duration naltrexone implantable pellet, as a potential treatment for methamphetamine use disorder. I look forward to helping BioCorRx position these approaches within a comprehensive, evidence-based system of care that expands treatment access, supports retention, and improves long-term recovery."
The appointment comes as the U.S. continues to grapple with high rates of opioid use disorder (OUD) and methamphetamine use disorder. According to the 2025 National Survey on Drug Use and Health, an estimated 4.0 million people in the United States aged 12 or older had an opioid use disorder in the past year, while approximately 2.7 million reported using methamphetamine in the past year and over 15 million have used it at least once in their lifetime. BioCorRx is conducting an ongoing NIDA-supported clinical study of BICX104, alone and in combination with bupropion, as a potential treatment for methamphetamine use disorder. The current clinical study is supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health under Award Number U01DA059994.
Baum's advisory role could prove critical as BioCorRx seeks to expand access to its programs, including its Beat Addiction Recovery program and UnCraveRx® Weight Loss Program. His deep understanding of federal drug policy and public health frameworks may help the company navigate regulatory pathways and build partnerships with government agencies and healthcare systems. For more information on BioCorRx and its pipeline, visit www.BioCorRx.com.
